Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells

BackgroundHypermethylation of the promoter of the tumor suppressor gene RASSF1A silences its expression and has been found to be associated with advanced grade prostatic tumors. The DNA methyltransferase (DNMT) family of enzymes are known to be involved in the epigenetic silencing of gene expression, including RASSF1A, and are often overexpressed in prostate cancer. The present study demonstrates how mahanine, a plant-derived carbazole alkaloid, restores RASSF1A expression by down-regulating specific members of the DNMT family of proteins in prostate cancer cells.ResultsUsing methylation-specific PCR we establish that mahanine restores the expression of RASSF1A by inducing the demethylation of its promoter in prostate cancer cells. Furthermore, we show that mahanine treatment induces the degradation of DNMT1 and DNMT3B, but not DNMT3A, via the ubiquitin-proteasome pathway; an effect which is rescued in the presence of a proteasome inhibitor, MG132. The inactivation of Akt by wortmannin, a PI3K inhibitor, results in a similar down-regulation in the levels DNMT1 and DNMT3B. Mahanine treatment results in a decline in phospho-Akt levels and a disruption in the interaction of Akt with DNMT1 and DNMT3B. Conversely, the exogenous expression of constitutively active Akt inhibits the ability of mahanine to down-regulate these DNMTs, suggesting that the degradation of DNMT1 and DNMT3B by mahanine occurs via Akt inactivation.ConclusionsTaken together, we show that mahanine treatment induces the proteasomal degradation of DNMT1 and DNMT3B via the inactivation of Akt, which facilitates the demethylation of the RASSF1A promoter and restores its expression in prostate cancer cells. Therefore, mahanine could be a potential therapeutic agent for advanced prostate cancer in men when RASSF1A expression is silenced.

[1]  S. Greer,et al.  Exploitation of elevated pyrimidine deaminating enzymes for selective chemotherapy. , 1989, Pharmacology & therapeutics.

[2]  A. V. Starikov,et al.  Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation , 2006, British Journal of Cancer.

[3]  Rudolf Jaenisch,et al.  Targeted mutation of the DNA methyltransferase gene results in embryonic lethality , 1992, Cell.

[4]  D. Tindall,et al.  Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. , 2001, Endocrinology.

[5]  A. Protopopov,et al.  The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. , 2002, Cancer research.

[6]  Xiaodong Cheng,et al.  A methylation and phosphorylation switch between an adjacent lysine and serine determines human DNMT1 stability , 2011, Nature Structural &Molecular Biology.

[7]  M. Chau,et al.  Development of a STAT3 reporter prostate cancer cell line for high throughput screening of STAT3 activators and inhibitors. , 2008, Biochemical and biophysical research communications.

[8]  G. Curt,et al.  A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880). , 1985, Cancer research.

[9]  R. Roberts,et al.  Genetic analysis of the 5-azacytidine sensitivity of Escherichia coli K-12 , 1987, Journal of bacteriology.

[10]  S. Pradhan,et al.  Regulation of expression and activity of DNA (cytosine-5) methyltransferases in mammalian cells. , 2011, Progress in molecular biology and translational science.

[11]  David A Jones,et al.  Reactivating the expression of methylation silenced genes in human cancer , 2002, Oncogene.

[12]  Gavin Sherlock,et al.  DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. , 2011, Genome research.

[13]  T. Brown,et al.  Increased androgen receptor expression correlates with development of age-dependent, lobe-specific spontaneous hyperplasia of the brown Norway rat prostate. , 2001, Endocrinology.

[14]  W. Farrar,et al.  IL-6 enhances the nuclear translocation of DNA cytosine-5-methyltransferase 1 (DNMT1) via phosphorylation of the nuclear localization sequence by the AKT kinase. , 2007, Cancer genomics & proteomics.

[15]  R. Jaenisch,et al.  Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Jaenisch,et al.  Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Akashi,et al.  Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. , 2001, Blood.

[18]  S. Kyo,et al.  Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. , 2006, Cancer research.

[19]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[20]  Swati Sinha,et al.  Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells. , 2007, Biochemical and biophysical research communications.

[21]  A. Marzo,et al.  Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. , 1999, Cancer research.

[22]  Swati Sinha,et al.  Mahanine inhibits growth and induces apoptosis in prostate cancer cells through the deactivation of Akt and activation of caspases , 2006, The Prostate.

[23]  S. Hirohashi,et al.  Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas , 2003, International journal of cancer.

[24]  R. Dahiya,et al.  DNA methyltransferase and demethylase in human prostate cancer , 2002, Molecular carcinogenesis.

[25]  H. Hsu,et al.  Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. , 2007, Lung cancer.

[26]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[27]  S. Kitano,et al.  Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. , 2004, The American journal of pathology.

[28]  D. Gold,et al.  Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation , 2008, Nature Genetics.

[29]  K. Ghoshal,et al.  5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal , 2005, Molecular and Cellular Biology.

[30]  R. Agarwal,et al.  Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. , 2000, Carcinogenesis.

[31]  B. Coffee.  Methylation‐Specific PCR , 2009, Current protocols in human genetics.

[32]  Hongbo Zhao,et al.  Phosphatidylinositol 3-kinase/protein kinase B pathway stabilizes DNA methyltransferase I protein and maintains DNA methylation. , 2007, Cellular signalling.

[33]  B. Zani,et al.  Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. , 2011, Endocrinology.

[34]  I. Bièche,et al.  Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  G. Pfeifer,et al.  Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. , 2003, Histology and histopathology.

[36]  G. Pfeifer,et al.  Methylation of the RASSF1A Gene in Human Cancers , 2002, Biological chemistry.

[37]  A. Protopopov,et al.  The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Manel Esteller,et al.  DNA demethylating agents and chromatin-remodelling drugs: which, how and why? , 2003, Current drug metabolism.

[39]  G. Pfeifer,et al.  Frequent hypermethylation of the RASSF1A gene in prostate cancer , 2002, Oncogene.